Skip to main content

Table 2 Age, gender, VTE incidence and all-cause mortality following hip arthroplasty in relation to indication for surgery

From: Symptomatic venous thromboembolism and mortality in orthopaedic surgery – an observational study of 45 968 consecutive procedures

Type of surgery Number of procedures (n = 4001) Median age- (25th-75th percentile) Female gender - n (%) Mortality – n (%) All VTE – n (%; 95% CI) PE – n (%; 95% CI) DVT – n (%; 95% CI)
Total hip replacement        
-Degenerative hip disorder 1691 71.1 (62–78) 1101 (65.1) 10 (0.6; 0.3-1.1) 40 (2.4; 1.7-3.2) 14 (0.8; 0.5-1.4) 28 (1.7; 1.1-2.4)
- Fracture 348 78.5 (73–83) 272 (78.2) 9 (2.6; 1.3-5.0) 10 (2.9; 1.5-5.3) 3 (0.9; 0.3-2.7) 7 (2.0; 1.0-4.2)
- Fracture sequelae 522 77.9 (70–84) 392 (75.1) 13 (2.5; 1.4-4.3) 14 (2.7; 1.6-4.5) 6 (1.2; 0.5-2.6) 8 (1.5; 0.8-3.1)
Hemiarthroplasty        
- hip fracture 743 84.9 (80–89) 565 (76.0) 71 (9.6; 7.6-12.1) 7 (0.9; 0.4-2.0) 6 (0.8; 0.4-1.8) 1 (0.1; 0.02-1.0)
- Fracture sequelae 239 84.9 (81–90) 192 (80.3) 15 (6.3; 3.8-10.4) 3 (1.3; 0.4-3.9) 0 3 (1.3; 0.4-3.9)
Hip prosthesis revision 429 74.8 (64–82) 251 (58.5) 3 (0.7; 0.2-2.2) 5 (1.2; 0.5-2.8) 0 5 (1.2; 0.5-2.8)
Hip replacement - malignancy 29 64.3 (58–78) 21 (72.4) 1 (3.4; 0.5-24.5) 1 (3.4; 0.5-24.5) 0 1 (3.4; 0.5-24.5)
  1. Thromboprophylaxis was used for 7 to 10 days.
  2. Fracture sequelae = osteonecrosis of the femoral head or non-union and or implant failure after hip fracture surgery.